

ABSTRAK BIODATA PENYELIDIKAN

Tajuk Penyelidikan:

RETROSPECTIVE SEVEN YEARS ANALYSIS OF DEXAMETHASONE THERAPY IN PRETERM PREGNANCY ADMITTED TO HOSPITAL UNIVERSITY SAINS MALAYSIA FROM THE YEAR 2003 TO 2009

DR ROSLAN BIN RIDZUAN
(MMed Obstetrik & Ginekologi)

DEPARTMENT OF OBSTETRIK & GINEKOLOGI
SCHOOL OF MEDICAL SCIENCES
UNIVERSITI SAINS MALAYSIA
HEALTH CAMPUS
16150 KELANTAN, MALAYSIA

Introduction

Prematurity is the main cause of neonatal morbidity and mortality. Antenatal corticosteroid therapy has been shown to markedly reduced complications of prematurity. A complete course of antenatal corticosteroid treatment is recommended to prevent pulmonary complications of preterm infants. Repeating courses of antenatal corticosteroid in mothers who are at risk of preterm delivery is still debatable.

Objectives

The primary objective of the study is to examine the association between different doses of antenatal intramuscular (IM) dexamethasone therapy and fetal respiratory outcomes.

Methodology

Retrospective study on case records of patients who delivered preterm and received antenatal IM dexamethasone therapy in HUSM from the year 2003 to 2009. Those who received IM dexamethasone 12.5 mg upon admission or diagnosis, followed by another dose of IM dexamethasone 12.5 mg, 12 hours later (total of 25 mg per day), is defined to receive a complete course of IM dexamethasone. Those who did not complete two doses of IM dexamethasone 12.5 mg, 12 hours apart is defined to receive incomplete course of IM dexamethasone. Those who were given another doses of IM dexamethasone after 1 week or more of the first course, is defined to receive repeat course of IM dexamethasone. Their babies' case records were reviewed to assess the fetal respiratory outcomes.

Results

We reviewed 927 case records of mothers who delivered preterm in HUSM from the year 2003 to 2009, and 980 case records of their newborns. There were 407 of mothers received incomplete, 484 received complete and 36 received repeat course of IM dexamethasone. Thence, 435 infants exposed to incomplete, 503 infants exposed to complete and 42 infants

exposed to repeated courses of antenatal IM dexamethasone for analysis. There were 61 infants delivered at 24 to 28 completed weeks, 515 infants delivered at more than 28 to 34 completed weeks, and 404 infants delivered at more than 34 to less than 37 completed weeks. In the group of infants who were delivered at more than 28 to 34 completed weeks gestation, a complete course of antenatal IM dexamethasone is significantly associated with better respiratory outcomes compared to those infants who were exposed to an incomplete course of antenatal IM dexamethasone. However, in the group of infants who were delivered at 24 to 28 completed weeks gestation as well as those delivered at more than 34 to less than 37 completed weeks period of gestation, there was no significant association between complete or incomplete course of antenatal IM dexamethasone and the respiratory outcomes.

Conclusions

A complete course of antenatal IM dexamethasone therapy significantly reduces the respiratory complications in the preterm infants delivered at more than 28 to 34 completed weeks period of gestation compared to those who were exposed to incomplete course of antenatal IM dexamethasone.

(Penyelia Utama: Associate Professor Dr Shah Reza Johan Nor)

(Penyelia Bersama: Dr Mohd Ismail Ibrahim)

**RETROSPECTIVE SEVEN YEARS ANALYSIS OF
DEXAMETHASONE THERAPY IN PRETERM
PREGNANCY ADMITTED TO HOSPITAL
UNIVERSITY SAINS MALAYSIA FROM THE YEAR
2003 TO 2009**

BY

DR ROSLAN BIN RIDZUAN

**Dissertation Submitted
In Partial Fulfillment Of The Requirements For
The Degree Of
Master In Obstetrics & Gynecology**



UNIVERSITI SAINS MALAYSIA

**UNIVERSITI SAINS MALAYSIA
2010**

TABLE OF CONTENTS

TABLES AND FIGURES	2
LIST OF ABBREVIATIONS	7
ACKNOWLEDGEMENTS	9
ABSTRACT (MALAY VERSION)	11
ABSTRACT (ENGLISH VERSION)	15
1 INTRODUCTION AND LITERATURE REVIEW	
1.1 INTRODUCTION	18
1.2 LITERATURE REVIEW	29
2 STUDY OBJECTIVES AND METHODOLOGY	
2.1 STUDY OBJECTIVES	38
2.2 METHODOLOGY	39
3 RESULTS	46
4 DISCUSSION	101
5 CONCLUSION	114
6 LIMITATION AND RECOMMENDATION	115
7 REFERENCES	118

TABLES AND FIGURES

TABLES

Table 1	Age distribution among patients with preterm delivery in HUSM from 2003 to 2009	48
Table 2	Race of patients with preterm delivery during the study period	50
Table 3	Gravida distribution among preterm women during the study period	52
Table 4	Period of gestation at delivery among the preterm women	54
Table 5	Order of pregnancy of the preterm women	56
Table 6	Medical diseases complicating pregnancy among the preterm women	58
Table 7	Antenatal complications in the preterm women	60
Table 8	Previous obstetric complications among the preterm women.	62
Table 9	Previous gynaecological complications among the preterm women	64
Table 10	Mode of delivery among the preterm women	66
Table 11	Associated conditions at presentation among the preterm women presented to HUSM	68
Table 12	Proportion of preterm women who received different doses of antenatal corticosteroids	70
Table 13	Proportion of infants whose mother received different doses of antenatal corticosteroids	71
Table 14	Proportion of infants delivered at different gestation period.	72
Table 15	Number of infants who were delivered at different gestation period and whose mothers received different doses of IM dexamethasone	73

Table 16	Mode of delivery of infants delivered at 28 to 34 weeks POG and received repeated courses IM dexamethasone	75
Table 17	Mode of delivery of infants delivered at 34 to 37 week POG and received repeated courses IM dexamethasone	76
Table 18	Mode of delivery of infants who were delivered at 24 to 28 completed weeks period of gestation	77
Table 19	The mean birth weight of infants who were delivered at 24 to 28 completed weeks period of gestation	78
Table 20	Courses of IM dexamethasone versus RDS in neonates delivered at 24 to 28 completed weeks period of gestation	79
Table 21	Courses of IM dexamethasone versus surfactant in neonates delivered at 24 to 28 completed weeks period of gestation	80
Table 22	Courses of IM dexamethasone versus number of doses of surfactant given in neonates delivered at 24 to 28 completed weeks period of gestation	81
Table 23	Courses of IM dexamethasone versus NICU admission in neonates delivered at 24 to 28 completed weeks period of gestation	82
Table 24	Courses of IM dexamethasone versus mean number of days admitted to ICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at 24 to 28 completed weeks period of gestation	83
Table 25	Mode of delivery of infants who were delivered at more than 28 to 34 completed weeks period of gestation	85

Table 26	The birth weight of infants who were delivered at more than 28 to 34 completed weeks period of gestation	86
Table 27	Courses of IM dexamethasone versus RDS in neonates delivered at more than 28 to 34 completed weeks period of gestation	87
Table 28	Courses of IM dexamethasone versus surfactant use in neonates delivered at more than 28 to 34 completed weeks period of gestation	88
Table 29	Courses of IM dexamethasone versus number of doses of surfactant given to neonates delivered at more than 28 to 34 completed weeks period of gestation	89
Table 30	Courses of IM dexamethasone versus ICU admission in neonates delivered at more than 28 completed weeks to 34 completed week period of gestation	90
Table 31	Courses of IM dexamethasone versus mean number of days admitted to NICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at more than 28 to 34 completed weeks period of gestation	91
Table 32	Mode of delivery of infants who were delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	93
Table 33	The mean birth weight of infants who were delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	94
Table 34	Courses of IM dexamethasone versus RDS in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	95

Table 35	Courses of IM dexamethasone versus surfactant in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	96
Table 36	Courses of IM dexamethasone versus dose of surfactant given in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	97
Table 37	Courses of IM dexamethasone versus NICU admission in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	98
Table 38	Courses of IM dexamethasone versus mean number of days admitted to NICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	99

FIGURES

Figure 1	Age distribution among patients with preterm delivery in HUSM from 2003 to 2009	49
Figure 2	Race distributions among patients with preterm delivery from 2003 to 2009	51
Figure 3	Gravida distribution among patients delivered preterm from 2003 to 2009	53
Figure 4	Period of gestation at delivery among the preterm women from 2003 to 2009	55
Figure 5	Order of pregnancy of the preterm women from 2003 to 2009	57
Figure 6	Medical diseases complicating pregnancy among the preterm women from 2003 to 2009	59
Figure 7	Antenatal complications in preterm women from 2003 to 2009	61
Figure 8	Previous obstetric complications among the preterm women from 2003 to 2009	63
Figure 9	Previous gynaecological complications among the preterm women from 2003 to 2009	65
Figure 10	Mode of delivery among the preterm women from 2003 to 2009	67
Figure 11	Associated conditions at presentation among the preterm women presented to HUSM from 2003 to 2009	69

LIST OF ABBREVIATIONS

APH	Antepartum haemorrhage
CI	Confidence interval
CS	Caesarean section
D & C	Dilatation and curettage
EFW	Estimated fetal weight
GDM	Gestational diabetes mellitus
HRPZ II	Hospital Raja Perempuan Zainab II
HUSM	Hospital Universiti Sains Malaysia
IM	Intramuscular
IUGR	Intrauterine growth restriction
IVH	Intraventricular haemorrhage
MOD	Mode of delivery
NICU	Neonatal Intensive Care Unit
NIH	National Institutes of Health and Human Development
O&G	Obstetric & Gynaecology
PE	Pre-eclampsia
PIH	Pregnancy induced hypertension
POA	Period of amenorrhoea
POG	Period of gestation
PPROM	Preterm prelabour rupture of membrane
RCOG	Royal College of Obstetrician and Gynaecologist

RDS	Respiratory Distress Syndrome
RR	Relative risk
SD	Standard deviation
SGA	Small for gestational age
SPSS	Statistical Package for Social Studies
SVD	Spontaneous vaginal delivery
USA	United States of America
USM	Universiti Sains Malaysia
WHO	World Health Organisation

ACKNOWLEDGEMENTS

In the name of Allah, the most graceful and the most merciful, with His blessing had given me strength to complete this manuscript.

First of all I would like to take this opportunity to thank Associate Professor Dr Shah Reza Johan Nor (Consultant and Senior Lecturer, Department of Obstetrics and Gynaecology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia) for being my supervisor and guide me in preparing this manuscript. His critical thinking and comments helped me in making this manuscript a reality.

I would also like to thank my co-supervisor Dr Mohd Ismail Ibrahim (Senior Lecturer, Department of Public Health, School of Medical Sciences, Health Campus, Universiti Sains Malaysia) who gave me a guide in preparing the methodology and help me out in statistical analysis for this study. Without his generous help the statistical results would not have been possible.

I am indebted to many people who played a part to accomplish my thesis. Thus, I would like to take this opportunity to express my gratitude to all staffs in the record office of HUSM for giving me a full support and cooperation in tracing all the case records. Without their cooperation, this work would have not been possible.

I specially thank to my wife, Dr Puteri Nurbaya Mohamed Ismail, for her constant support and encouragement throughout my preparation for this thesis. To my daughter Aimi Sabrina and son, Amer Harris, thank you all for being patience and understanding kids.

ABSTRAK

Pengenalan

Kelahiran pramatang adalah suatu penyebab utama kepada kematian dan kecederaan atau penyakit di kalangan bayi yang baru lahir. Kajian menunjukkan bahawa rawatan kortikosteroid seperti suntikan ubat dexamethasone terbukti dapat mengurangkan pelbagai komplikasi di kalangan bayi yang lahir pramatang. Melengkapkan rawatan kortikosteroid semasa mengandung telah disyorkan kepada ibu – ibu mengandung yang berisiko untuk melahirkan bayi pramatang. Walaubagaimana pun, faedah dan keberkesanan mengulangi rawatan kortikosteroid setelah menerima rawatan lengkap tersebut masih lagi dalam perbincangan di kalangan pakar – pakar perbidanan dan sakit puan.

Objektif

Tujuan kajian ini adalah untuk menganalisa kaitan antara komplikasi system pernafasan di kalangan bayi yang lahir pramatang dengan bilangan rawatan kortikosteroid iaitu dexamethasone yang diberikan kepada ibu –ibu mereka semasa mengandung.

Metodologi

Kajian retrospektif dilakukan ke atas rekod pesakit yang telah melahirkan bayi pramatang dan telah menerima rawatan kortikosteroid semasa mengandung bayi tersebut di Hospital Universiti Sains Malaysia (HUSM) dari tahun 2003 hingga tahun 2009. Mereka yang menerima dua suntikan ubat dexamethasone 12.5 mg setiap suntikan dengan selang 12 jam setiap suntikan (25 mg sehari), sebelum bersalin ditafsirkan sebagai menerima rawatan lengkap dexamethasone. Mereka yang hanya sempat menerima satu suntikan dexamethasone 12.5 mg sebelum bersalin ditafsirkan sebagai menerima rawatan tidak lengkap dexamethasone. Manakala mereka yang menerima suntikan ulangan dexamethasone setelah seminggu atau lebih selepas melengkapkan rawatan lengkap tersebut adalah ditafsirkan sebagai menerima rawatan ulangan dexamethasone. Rekod rawatan bayi mereka dikaji untuk melihat komplikasi system pernafasan bayi tersebut.

Keputusan

Kami mengkaji sebanyak 927 rekod ibu-ibu mengandung yang melahirkan bayi pramatang dan sebanyak 980 rekod rawatan bayi mereka di HUSM dari tahun 2003 hingga 2009. Kami dapati sebanyak 407 orang ibu mengandung menerima rawatan tidak lengkap dexamethasone, sebanyak 484 orang ibu mengandung menerima rawatan lengkap dexamethasone, dan sebanyak 36 orang ibu mengandung menerima rawatan ulangan dexamethasone. Ini memberikan kami sebanyak 435 orang bayi dari mereka yang menerina rawatan tidak lengkap dexamethasone, 503 orang bayi dari mereka yang

menerima rawatan lengkap dexamethasone dan sebanyak 42 orang bayi dari mereka yang menerima rawatan ulangan dexamethasone untuk dianalisa. Terdapat 61 orang bayi yang dilahirkan pramatang pada jangkamasa kandungan 24 hingga 28 minggu lengkap, 515 bayi yang dilahirkan pramatang pada jangkamasa lebih dari 28 minggu hingga 34 minggu lengkap, 404 bayi yang dilahirkan pramatang pada jangkamasa lebih dari 34 minggu hingga kurang dari 37 minggu lengkap.

Didapati bayi yang dilahirkan pramatang, pada jangkamasa kandungan diantara lebih dari 28 minggu hingga 34 minggu lengkap, oleh ibu –ibu yang menerima rawatan lengkap dexamethasone mempunyai kadar kejadian RDS yang rendah, memerlukan rawatan surfactant yang kurang, mempunyai purata Apgar skor yang tinggi, memiliki jangkamasa rawatan di NICU yang pendek serta memerlukan jangkamasa bantuan mesin pernafasan yang singkat berbanding bayi yang mana ibu mereka menerima rawatan dexamethasone tidak lengkap. Kesemua perkaitan tersebut adalah signifikan dari segi statistic. Tetapi bagi bayi yang dilahirkan pramatang pada jangkamasa kandungan antara 24 minggu hingga 28 minggu lengkap dan juga pada jangkamasa kandungan diantara lebih dari 34 minggu hingga kurang dari 37 minggu lengkap, perkaitan antara rawatan lengkap atau tidak lengkap dexamethasone dan komplikasi pernafasan seperti yang tersebut di atas adalah tidak signifikan dari segi statistik.

Kesimpulan

Rawatan lengkap dexamethasone berkait rapat dengan pengurangan masalah komplikasi pernafasan di kalangan bayi yang dilahirkan pramatang pada jangkamasa kandungan diantara lebih dari 28 minggu hingga 34 minggu lengkap berbanding dengan perawatan dexamethasone yang tidak lengkap.

ABSTRACT

Introduction

Prematurity is the main cause of neonatal morbidity and mortality. Antenatal corticosteroid therapy has been shown to markedly reduced complications of prematurity. A complete course of antenatal corticosteroid treatment is recommended to prevent pulmonary complications of preterm infants. Repeating courses of antenatal corticosteroid in mothers who are at risk of preterm delivery is still debatable.

Objectives

The primary objective of the study is to examine the association between different doses of antenatal intramuscular (IM) dexamethasone therapy and fetal respiratory outcomes.

Methodology

Retrospective study on case records of patients who delivered preterm and received antenatal IM dexamethasone therapy in HUSM from the year 2003 to 2009. Those who received IM dexamethasone 12.5 mg upon admission or diagnosis, followed by another dose of IM dexamethasone 12.5 mg, 12 hours later (total of 25 mg per day), is defined to receive a complete course of IM dexamethasone. Those who did not complete two doses of IM dexamethasone 12.5 mg, 12 hours apart is defined to receive incomplete course of IM dexamethasone. Those who were given another doses of IM dexamethasone after 1 week or more of the first course, is defined to receive repeat course of IM

dexamethasone. Their babies' case records were reviewed to assess the fetal respiratory outcomes.

Results

We reviewed 927 case records of mothers who delivered preterm in HUSM from the year 2003 to 2009, and 980 case records of their newborns. There were 407 of mothers received incomplete, 484 received complete and 36 received repeat course of IM dexamethasone. Thence, 435 infants exposed to incomplete, 503 infants exposed to complete and 42 infants exposed to repeated courses of antenatal IM dexamethasone for analysis. There were 61 infants delivered at 24 to 28 completed weeks, 515 infants delivered at more than 28 to 34 completed weeks, and 404 infants delivered at more than 34 to less than 37 completed weeks. In the group of infants who were delivered at more than 28 to 34 completed weeks gestation, a complete course of antenatal IM dexamethasone is significantly associated with better respiratory outcomes compared to those infants who were exposed to an incomplete course of antenatal IM dexamethasone. However, in the group of infants who were delivered at 24 to 28 completed weeks gestation as well as those delivered at more than 34 to less than 37 completed weeks period of gestation, there was no significant association between complete or incomplete course of antenatal IM dexamethasone and the respiratory outcomes.

Conclusions

A complete course of antenatal IM dexamethasone therapy significantly reduces the respiratory complications in the preterm infants delivered at more than 28 to 34 completed weeks period of gestation compared to those who were exposed to incomplete course of antenatal IM dexamethasone.

TABLE OF CONTENTS

TABLES AND FIGURES	2
LIST OF ABBREVIATIONS	7
ACKNOWLEDGEMENTS	9
ABSTRACT (MALAY VERSION)	11
ABSTRACT (ENGLISH VERSION)	15
1 INTRODUCTION AND LITERATURE REVIEW	
1.1 INTRODUCTION	18
1.2 LITERATURE REVIEW	29
2 STUDY OBJECTIVES AND METHODOLOGY	
2.1 STUDY OBJECTIVES	38
2.2 METHODOLOGY	39
3 RESULTS	46
4 DISCUSSION	101
5 CONCLUSION	114
6 LIMITATION AND RECOMMENDATION	115
7 REFERENCES	118

TABLES AND FIGURES

TABLES

Table 1	Age distribution among patients with preterm delivery in HUSM from 2003 to 2009	48
Table 2	Race of patients with preterm delivery during the study period	50
Table 3	Gravida distribution among preterm women during the study period	52
Table 4	Period of gestation at delivery among the preterm women	54
Table 5	Order of pregnancy of the preterm women	56
Table 6	Medical diseases complicating pregnancy among the preterm women	58
Table 7	Antenatal complications in the preterm women	60
Table 8	Previous obstetric complications among the preterm women.	62
Table 9	Previous gynaecological complications among the preterm women	64
Table 10	Mode of delivery among the preterm women	66
Table 11	Associated conditions at presentation among the preterm women presented to HUSM	68
Table 12	Proportion of preterm women who received different doses of antenatal corticosteroids	70
Table 13	Proportion of infants whose mother received different doses of antenatal corticosteroids	71
Table 14	Proportion of infants delivered at different gestation period.	72
Table 15	Number of infants who were delivered at different gestation period and whose mothers received different doses of IM dexamethasone	73

Table 16	Mode of delivery of infants delivered at 28 to 34 weeks POG and received repeated courses IM dexamethasone	75
Table 17	Mode of delivery of infants delivered at 34 to 37 week POG and received repeated courses IM dexamethasone	76
Table 18	Mode of delivery of infants who were delivered at 24 to 28 completed weeks period of gestation	77
Table 19	The mean birth weight of infants who were delivered at 24 to 28 completed weeks period of gestation	78
Table 20	Courses of IM dexamethasone versus RDS in neonates delivered at 24 to 28 completed weeks period of gestation	79
Table 21	Courses of IM dexamethasone versus surfactant in neonates delivered at 24 to 28 completed weeks period of gestation	80
Table 22	Courses of IM dexamethasone versus number of doses of surfactant given in neonates delivered at 24 to 28 completed weeks period of gestation	81
Table 23	Courses of IM dexamethasone versus NICU admission in neonates delivered at 24 to 28 completed weeks period of gestation	82
Table 24	Courses of IM dexamethasone versus mean number of days admitted to ICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at 24 to 28 completed weeks period of gestation	83
Table 25	Mode of delivery of infants who were delivered at more than 28 to 34 completed weeks period of gestation	85

Table 26	The birth weight of infants who were delivered at more than 28 to 34 completed weeks period of gestation	86
Table 27	Courses of IM dexamethasone versus RDS in neonates delivered at more than 28 to 34 completed weeks period of gestation	87
Table 28	Courses of IM dexamethasone versus surfactant use in neonates delivered at more than 28 to 34 completed weeks period of gestation	88
Table 29	Courses of IM dexamethasone versus number of doses of surfactant given to neonates delivered at more than 28 to 34 completed weeks period of gestation	89
Table 30	Courses of IM dexamethasone versus ICU admission in neonates delivered at more than 28 completed weeks to 34 completed week period of gestation	90
Table 31	Courses of IM dexamethasone versus mean number of days admitted to NICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at more than 28 to 34 completed weeks period of gestation	91
Table 32	Mode of delivery of infants who were delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	93
Table 33	The mean birth weight of infants who were delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	94
Table 34	Courses of IM dexamethasone versus RDS in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	95

Table 35	Courses of IM dexamethasone versus surfactant in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	96
Table 36	Courses of IM dexamethasone versus dose of surfactant given in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	97
Table 37	Courses of IM dexamethasone versus NICU admission in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	98
Table 38	Courses of IM dexamethasone versus mean number of days admitted to NICU, mean number of days on ventilation, and mean Apgar score at first minute in neonates delivered at more than 34 completed weeks to less than 37 completed weeks period of gestation	99

FIGURES

Figure 1	Age distribution among patients with preterm delivery in HUSM from 2003 to 2009	49
Figure 2	Race distributions among patients with preterm delivery from 2003 to 2009	51
Figure 3	Gravida distribution among patients delivered preterm from 2003 to 2009	53
Figure 4	Period of gestation at delivery among the preterm women from 2003 to 2009	55
Figure 5	Order of pregnancy of the preterm women from 2003 to 2009	57
Figure 6	Medical diseases complicating pregnancy among the preterm women from 2003 to 2009	59
Figure 7	Antenatal complications in preterm women from 2003 to 2009	61
Figure 8	Previous obstetric complications among the preterm women from 2003 to 2009	63
Figure 9	Previous gynaecological complications among the preterm women from 2003 to 2009	65
Figure 10	Mode of delivery among the preterm women from 2003 to 2009	67
Figure 11	Associated conditions at presentation among the preterm women presented to HUSM from 2003 to 2009	69